Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis - Wikidata - awgldk - TriplyDB

Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis

Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis

http://www.wikidata.org/entity/Q37176577

about

Function, regulation and pathological roles of the Gab/DOS docking proteins Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?Aberrant neuronal activity-induced signaling and gene expression in a mouse model of RASopathy.PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.Frs2α and Shp2 signal independently of Gab to mediate FGF signaling in lens development.Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.SHP2E76K mutant promotes lung tumorigenesis in transgenic mice Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells.Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).SHP2 mediates the localized activation of Fyn downstream of the α6β4 integrin to promote carcinoma invasion.Protein tyrosine phosphatases as potential therapeutic targets.A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder Targeting protein tyrosine phosphatases for anticancer drug discovery.Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells.Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool.Protein-tyrosine phosphatase Shp2 positively regulates macrophage oxidative burst Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis.Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.Leukemogenic Ptpn11 allele causes defective erythropoiesis in mice.SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion.Molecular targets for the treatment of juvenile myelomonocytic leukemia.Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.Shp2 function in hematopoietic stem cell biology and leukemogenesis.Peripheral blood cells from children with RASopathies show enhanced spontaneous colonies growth in vitro and hyperactive RAS signaling.Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma Shp2 and Pten have antagonistic roles in myeloproliferation but cooperate to promote erythropoiesis in mammals Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles.Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies A comprehensive analysis of GATA-1-regulated miRNAs reveals miR-23a to be a positive modulator of erythropoiesis.Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation.Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling.Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.

P2860

Q21245511-FA092FB2-8480-42A4-8581-86E93B6C86EF Q26828777-EB3416C7-D870-400E-8B43-F556E0BEE04D Q30357327-D38BAB6B-4BD1-4429-9E16-6318B99EE995 Q33556937-1433C2EA-3189-40EB-B9AB-310930B4B218 Q33557690-7D05D438-6A44-4734-BD88-68E3478936D7 Q33774488-BE2E407B-A44E-4984-B7E3-2979A35A10BE Q34005613-22CDE92D-6F62-4889-8525-CF69C652125D Q34009953-C2DED9B3-9C1A-46F5-85B1-378AD2BBADB9 Q34136434-BB70A3AC-5B50-438C-8A6D-002D170AED77 Q34155125-018F267E-EA40-4530-B39C-E206A26A01BB Q34290934-CF5B3174-ABEA-4319-B124-487275D72548 Q34295063-0322E294-91A3-4135-9244-1C11CB6F9097 Q34310556-4C61B881-8E35-4449-9FBF-B7DD470C0CCD Q34627221-B20AE179-DFAC-4797-AA67-6927A7332BE2 Q34722748-06719FF3-FE37-4FBB-AA54-8EAD1EC1DB56 Q34789961-9F72474D-551A-48FF-995C-3B4125DDB303 Q34923711-FFE125C6-A56C-436B-B7E7-6A14AE6DD5E6 Q35029942-557C17CD-DC10-4713-A9F9-FB658B9D3998 Q35080194-F88BA17D-2290-4E08-B2D8-B6E2B9E431A4 Q35101627-66E271CB-7CB1-4EC4-A390-5388CE401180 Q35237519-0BAD64D1-89A3-4E44-AEBC-44F4994B90E3 Q35308167-1A71FC21-3E11-42CD-B9AE-096C23ADC726 Q35555130-D870987E-C553-4D8B-ABAD-F9AA04A54898 Q35579349-4B073DAA-945D-4A66-B675-C3213167EE9F Q35685296-E9B4085A-6B2F-4F3D-B1D5-11E4E0E8D92F Q35825659-701E4169-8CFA-47A6-8995-5AEFF8F13C08 Q35921878-D679DAC2-1680-436B-9BE7-3D9D26218D5E Q35943238-B1E38DA7-458D-4293-9D6A-87F55A6BC309 Q36238390-F2460A8C-D8B5-412F-9D76-CA0D9C3D78C8 Q36455309-97941D09-CEA9-40E2-BE01-D9E9D7A2A1DC Q36551546-03DFFA25-30A1-4594-9A56-ED0683884F81 Q36769475-1684DD9B-3E71-423A-B755-74CD7A01867B Q36800462-E67DF801-84B3-4142-9B66-8B5AAAF4DBDF Q36905741-414439B9-04AA-4FDE-A600-C24EE486A9FD Q37112471-0E4AA0FE-C42B-43CD-983B-8B23D82DD111 Q37161507-D13015E5-80DD-45D1-9EF6-3710A1BEE24B Q37302271-34AC2E5F-C585-4538-B673-1304BBC1A96E Q37409325-4D2A7225-0552-4488-8C65-8B518BFFDF88 Q37653117-B06B03A4-D613-48ED-B33B-1BBA1750D343 Q37688327-FBE30F6E-3DED-4A52-8F94-C4C970C31F32

P2860

Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis

http://www.wikidata.org/entity/Q37176577

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Leukemogenic Ptpn11 causes fat ...... ltiple stages of hematopoiesis

@en

Leukemogenic Ptpn11 causes fat ...... tiple stages of hematopoiesis.

@nl

type

label

Leukemogenic Ptpn11 causes fat ...... ltiple stages of hematopoiesis

@en

Leukemogenic Ptpn11 causes fat ...... tiple stages of hematopoiesis.

@nl

prefLabel

Leukemogenic Ptpn11 causes fat ...... ltiple stages of hematopoiesis

@en

Leukemogenic Ptpn11 causes fat ...... tiple stages of hematopoiesis.

@nl

P1433

Q37176577-9EB88A91-726D-4AC6-8E60-056A85F78908

P1476

Q37176577-4E3611D1-571C-45D7-A494-20AA9A79D7DE

P2093

Q37176577-304B0F6E-DBA5-422F-8CD4-F32200BC2F7E

Q37176577-83C3B987-4983-41B3-BB7A-757EC76D2D2A

Q37176577-8B0BF902-54D4-4235-BC91-8A78BF226DB6

Q37176577-9C0F713C-E546-42C7-9C18-0D97DD7C7AC7

Q37176577-AA52A0E4-AC92-4E8E-B529-8B203AA11B49

Q37176577-B401EAA8-13E9-4F18-A69E-51E5415DB8E1

Q37176577-C82DB49D-D447-4AEB-B826-17EB23E15B89

P2860

Q37176577-01E4D7D3-F0C9-4EC8-B0D9-8C5C3C5F51DC

Q37176577-034CFBC8-522F-40ED-933A-D15C4FEB9E6F

Q37176577-0648A204-C4ED-4568-8028-816CEB7C5301

Q37176577-08979120-AD15-44B8-B035-D78CD661733C

Q37176577-11A9E24A-A5E4-44F9-964C-5F70024DB100

Q37176577-14F1CE43-5D5A-462D-9755-C361C0B4FAA8

Q37176577-18F209E1-3C29-4E23-9E84-60C23757C909

Q37176577-1C627562-D26C-4F29-904E-C2101A72CDBA

Q37176577-1CD65C04-595A-4194-BC8E-A8B32304C093

Q37176577-273A9587-4E36-406A-B87A-01DC353EF8B8

P304

Q37176577-580CD14B-E08A-4EA9-BCCD-AD9C315CCF33

P31

Q37176577-BBAAE04E-10E3-4BC5-AA0A-D2FCD252132F

P356

Q37176577-5D0480DA-F039-4364-96D9-35C1B01DBEFC

P407

Q37176577-B2DCFDEE-EB5E-40EA-9659-AEEE116C0076

P433

Q37176577-D688FBED-62C2-4C1E-8443-71CB04B70DAA

P478

Q37176577-4B9D366A-537E-49AC-AB7E-3BB1099AED12

P577

Q37176577-2311A000-7AC3-4A94-B723-EADF65E29E77

P5875

Q37176577-93D34EDD-224B-40AB-9CAF-27BB7AEDF437

P698

Q37176577-9A2ECF23-AF10-467D-9CB9-24CF72D8F57E

P921

Q37176577-03F6E342-7BCE-4120-A8A8-5EBD4ABC92E6

P932

Q37176577-19A15688-33DF-41BB-A6CB-9DA04C353334

P356

BLOOD-2008-10-182626

P1433

P1476

Leukemogenic Ptpn11 causes fat ...... ltiple stages of hematopoiesis

@en

P2093

Benjamin G Neel

http://www.w3.org/2001/XMLSchema#string

Demetrios Kalaitzidis

http://www.w3.org/2001/XMLSchema#string

Gordon Chan

http://www.w3.org/2001/XMLSchema#string

Jeffery L Kutok

http://www.w3.org/2001/XMLSchema#string

M Golam Mohi

http://www.w3.org/2001/XMLSchema#string

Tatiana Usenko

http://www.w3.org/2001/XMLSchema#string

Wentian Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome

Crystal structure of the tyrosine phosphatase SHP-2

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Nf1 and Gmcsf interact in myeloid leukemogenesis

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation

Efficient in vivo manipulation of mouse genomic sequences at the zygote stage

Inducible gene targeting in mice

SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells

Hyperactive Ras in developmental disorders and cancer

P304

4414-4424

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-10-182626

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23959565

http://www.w3.org/2001/XMLSchema#string

P698

19179468

http://www.w3.org/2001/XMLSchema#string

P921

P932

2676094

http://www.w3.org/2001/XMLSchema#string